Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

Paul Thurmes, Timothy Call, Susan L Slager, Clive Zent, Gregory Jenkins, Susan Schwager, Deborah Bowen, Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic leukemia (CLL). We investigated the prevalence and prognostic implications of comorbidities in patients with newly diagnosed CLL. Local/non-referred patients with CLL evaluated by a hematologist at Mayo Clinic within 1 year of diagnosis were eligible for this retrospective review. Of 1195 individuals evaluated for newly-diagnosed CLL between 1995 and 2006, 373 (31%) were local/ non-referred. At diagnosis, 89% of these patients had one or more comorbidities, and 46% had at least one major comorbidity. Twenty-six percent of patients failed to meet NCI working group guidelines to participate in a clinical trial. On multi-factor analysis, Rai risk category (1.39 per each risk category increase; p<0.0001) and age (1.056 per year increase; p<0.0001) were the only factors associated with overall survival. We conclude that, although common, comorbid conditions are less important than age and stage in predicting prognosis in newly diagnosed patients with CLL. Clinical trials evaluating treatments that are designed to be tolerated by patients who do not meet traditional clinical trial eligibility criteria are needed.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalLeukemia and Lymphoma
Volume49
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Survival
Comorbidity
Clinical Trials
Statistical Factor Analysis
Guidelines

Keywords

  • Chronic lymphocytic leukemia
  • Co-morbidity
  • Organ function
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. / Thurmes, Paul; Call, Timothy; Slager, Susan L; Zent, Clive; Jenkins, Gregory; Schwager, Susan; Bowen, Deborah; Kay, Neil Elliot; Shanafelt, Tait D.

In: Leukemia and Lymphoma, Vol. 49, No. 1, 01.2008, p. 49-56.

Research output: Contribution to journalArticle

Thurmes, Paul ; Call, Timothy ; Slager, Susan L ; Zent, Clive ; Jenkins, Gregory ; Schwager, Susan ; Bowen, Deborah ; Kay, Neil Elliot ; Shanafelt, Tait D. / Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 1. pp. 49-56.
@article{b82a885d650747cf8cce1f0bfd9964bb,
title = "Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia",
abstract = "Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic leukemia (CLL). We investigated the prevalence and prognostic implications of comorbidities in patients with newly diagnosed CLL. Local/non-referred patients with CLL evaluated by a hematologist at Mayo Clinic within 1 year of diagnosis were eligible for this retrospective review. Of 1195 individuals evaluated for newly-diagnosed CLL between 1995 and 2006, 373 (31{\%}) were local/ non-referred. At diagnosis, 89{\%} of these patients had one or more comorbidities, and 46{\%} had at least one major comorbidity. Twenty-six percent of patients failed to meet NCI working group guidelines to participate in a clinical trial. On multi-factor analysis, Rai risk category (1.39 per each risk category increase; p<0.0001) and age (1.056 per year increase; p<0.0001) were the only factors associated with overall survival. We conclude that, although common, comorbid conditions are less important than age and stage in predicting prognosis in newly diagnosed patients with CLL. Clinical trials evaluating treatments that are designed to be tolerated by patients who do not meet traditional clinical trial eligibility criteria are needed.",
keywords = "Chronic lymphocytic leukemia, Co-morbidity, Organ function, Prognosis",
author = "Paul Thurmes and Timothy Call and Slager, {Susan L} and Clive Zent and Gregory Jenkins and Susan Schwager and Deborah Bowen and Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2008",
month = "1",
doi = "10.1080/10428190701724785",
language = "English (US)",
volume = "49",
pages = "49--56",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

AU - Thurmes, Paul

AU - Call, Timothy

AU - Slager, Susan L

AU - Zent, Clive

AU - Jenkins, Gregory

AU - Schwager, Susan

AU - Bowen, Deborah

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2008/1

Y1 - 2008/1

N2 - Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic leukemia (CLL). We investigated the prevalence and prognostic implications of comorbidities in patients with newly diagnosed CLL. Local/non-referred patients with CLL evaluated by a hematologist at Mayo Clinic within 1 year of diagnosis were eligible for this retrospective review. Of 1195 individuals evaluated for newly-diagnosed CLL between 1995 and 2006, 373 (31%) were local/ non-referred. At diagnosis, 89% of these patients had one or more comorbidities, and 46% had at least one major comorbidity. Twenty-six percent of patients failed to meet NCI working group guidelines to participate in a clinical trial. On multi-factor analysis, Rai risk category (1.39 per each risk category increase; p<0.0001) and age (1.056 per year increase; p<0.0001) were the only factors associated with overall survival. We conclude that, although common, comorbid conditions are less important than age and stage in predicting prognosis in newly diagnosed patients with CLL. Clinical trials evaluating treatments that are designed to be tolerated by patients who do not meet traditional clinical trial eligibility criteria are needed.

AB - Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic leukemia (CLL). We investigated the prevalence and prognostic implications of comorbidities in patients with newly diagnosed CLL. Local/non-referred patients with CLL evaluated by a hematologist at Mayo Clinic within 1 year of diagnosis were eligible for this retrospective review. Of 1195 individuals evaluated for newly-diagnosed CLL between 1995 and 2006, 373 (31%) were local/ non-referred. At diagnosis, 89% of these patients had one or more comorbidities, and 46% had at least one major comorbidity. Twenty-six percent of patients failed to meet NCI working group guidelines to participate in a clinical trial. On multi-factor analysis, Rai risk category (1.39 per each risk category increase; p<0.0001) and age (1.056 per year increase; p<0.0001) were the only factors associated with overall survival. We conclude that, although common, comorbid conditions are less important than age and stage in predicting prognosis in newly diagnosed patients with CLL. Clinical trials evaluating treatments that are designed to be tolerated by patients who do not meet traditional clinical trial eligibility criteria are needed.

KW - Chronic lymphocytic leukemia

KW - Co-morbidity

KW - Organ function

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=38549168905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549168905&partnerID=8YFLogxK

U2 - 10.1080/10428190701724785

DO - 10.1080/10428190701724785

M3 - Article

VL - 49

SP - 49

EP - 56

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -